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Abstract: Background Diffuse gliomas exhibit diffuse infiltrative growth, often beyond the magnetic
resonance imaging (MRI)-detectable tumor lesion. Within this lesion, hypermetabolism and impaired
cerebrovascular reactivity (CVR) are found, but its exact distribution pattern into the peritumoral
environment is unknown. Our aim was to better characterize the extent of diffuse glioma tissue in-
filtration, beyond the visible lesion (ie, beyond the T1-contrast-enhancing lesion and/or T2/FLAIR-
defined tumor border), with metabolic positron emission tomography (PET), and functional MRI CVR
(blood oxygenation-level-dependent CVR [BOLD-CVR]) mapping. Methods From a prospective glioma
database, 18 subjects (19 datasets) with diffuse glioma (n = 2 with anaplastic astrocytoma, n = 10 with
anaplastic oligodendroglioma, and n = 7 with glioblastoma) underwent a BOLD-CVR and metabolic
PET study between February 2016 and September 2019, 7 of them at primary diagnosis and 12 at tumor
recurrence. In addition, 19 matched healthy controls underwent an identical BOLD-CVR study. The
tumor lesion was defined using high-resolution anatomical MRI. Volumes of interest starting from the
tumor lesion outward up to 30 mm were created for a detailed peritumoral PET and BOLD-CVR tissue
analysis. Student’s t test was used for statistical analysis. Results Patients with diffuse glioma exhibit
impaired BOLD-CVR 12 mm beyond the tumor lesion (P = .02) with normalization of BOLD-CVR val-
ues after 24 mm. Metabolic PET shows a difference between the affected and contralateral hemisphere
of 6 mm (P = .05) with PET values normalization after 12 mm. Conclusion We demonstrate hyperme-
tabolism and impaired CVR beyond the standard MRI-defined tumor border, suggesting active tumor
infiltration in the peritumoral environment.
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Abstract
Background. Diffuse gliomas exhibit diffuse infiltrative growth, often beyond the magnetic resonance imaging 
(MRI)-detectable tumor lesion. Within this lesion, hypermetabolism and impaired cerebrovascular reactivity (CVR) 
are found, but its exact distribution pattern into the peritumoral environment is unknown. Our aim was to better 
characterize the extent of diffuse glioma tissue infiltration, beyond the visible lesion (ie, beyond the T1-contrast-
enhancing lesion and/or T2/FLAIR-defined tumor border), with metabolic positron emission tomography (PET), and 
functional MRI CVR (blood oxygenation-level-dependent CVR [BOLD-CVR]) mapping.
Methods. From a prospective glioma database, 18 subjects (19 datasets) with diffuse glioma (n = 2 with anaplastic 
astrocytoma, n = 10 with anaplastic oligodendroglioma, and n = 7 with glioblastoma) underwent a BOLD-CVR and 
metabolic PET study between February 2016 and September 2019, 7 of them at primary diagnosis and 12 at tumor 
recurrence. In addition, 19 matched healthy controls underwent an identical BOLD-CVR study. The tumor lesion 
was defined using high-resolution anatomical MRI. Volumes of interest starting from the tumor lesion outward up 
to 30 mm were created for a detailed peritumoral PET and BOLD-CVR tissue analysis. Student’s t test was used for 
statistical analysis.
Results. Patients with diffuse glioma exhibit impaired BOLD-CVR 12 mm beyond the tumor lesion (P = .02) with 
normalization of BOLD-CVR values after 24 mm. Metabolic PET shows a difference between the affected and con-
tralateral hemisphere of 6 mm (P = .05) with PET values normalization after 12 mm.
Conclusion. We demonstrate hypermetabolism and impaired CVR beyond the standard MRI-defined tumor border, 
suggesting active tumor infiltration in the peritumoral environment.
Key Points
 • Hypermetabolism and impaired CVR beyond the standard diffuse glioma border.
 • Active infiltration of diffuse glioma in the peritumoral environment.
 • Combined hemodynamic and metabolic approach to identify diffuse glioma infiltration.
Hypermetabolism and impaired cerebrovascular 
reactivity beyond the standard MRI-identified tumor 
border indicate diffuse glioma extended tissue 
infiltration
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 2 Sebök et al. Diffuse gliomas’ peritumoral environment
Diffuse gliomas exhibit heterogeneous metabolic and he-
modynamic properties, resulting in an erratic growth 
pattern.1,2 This behavior is reflected in neuroimaging chal-
lenges, where the tumor infiltration zone usually exceeds 
the contrast-enhancing lesion on T1-weighted magnetic 
resonance imaging (MRI), and often does not exactly match 
the metabolic “hot spots” seen on O-(2-[18F]fluoroethyl)-L-
tyrosine-positron emission tomography (FET-PET).3–5 Since 
accurate delineation of the tumor infiltration zone holds 
great therapeutic and prognostic value, multimodal neu-
roimaging approaches are now considered state-of-the-art 
in order to obtain the most comprehensive tumor imaging 
characterization.
In this regard, blood oxygenation-level-dependent 
(BOLD) functional MRI (fMRI) cerebrovascular reactivity 
(CVR) may provide important complementary hemody-
namic information.6–8 For noninvasive assessment of brain 
function to evaluate diffuse glioma surgery in eloquent 
brain areas, BOLD fMRI is already increasingly used.9 
BOLD fMRI can be enhanced with a controlled carbon di-
oxide (CO2) stimulus, to allow for detailed CVR mapping 
of the contrast-enhancing glioma lesion as well as the 
peritumoral—infiltrative—tumor zone.8,10,11 This is of par-
ticular interest for the non-contrast-enhancing tumor infil-
tration zone, where gliomas are believed to cause vascular 
dysregulation, and neurovascular uncoupling.6,8,10,11
Therefore, by acquiring metabolic and hemodynamic 
neuroimaging data, the extent of diffuse glioma-related 
tissue disturbances can be investigated. For this study, we 
aimed at better characterizing diffuse tissue infiltration of 
diffuse gliomas, beyond the classically defined tumor le-
sion (ie, beyond the T1 contrast-enhancing lesion and/or 
T2/FLAIR-defined tumor border), with metabolic PET, and 
BOLD-CVR mapping.
Materials and Methods
At the Clinical Neuroscience Center of University Hospital 
Zurich, patients with IDH-mutant, 1p/19-codeleted 
anaplastic oligodendroglioma (n  =  9), IDH-mutant 
anaplastic astrocytoma (n  =  2), or IDH-wildtype glioblas-
toma (n  = 7) according to the 2016 WHO classification,1,2 
primary or recurrent, were selected from a prospective 
database based on following inclusion criteria: patients 
with age older than 18 years who underwent both a he-
modynamic BOLD-CVR imaging and a metabolic imaging 
with either FET-PET or fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) within the time frame of 6 
weeks. Both metabolic PET and BOLD-CVR investiga-
tions were performed after the routine contrast-enhanced 
T1-weighted imaging. The patients underwent BOLD-CVR 
imaging in additional MR sessions to prevent that CVR re-
sults would be affected post-contrast-enhanced.
The study was conducted between February 2016 and 
September 2019. All the subjects signed an informed con-
sent before participation in this study. The Cantonal Ethics 
Committee of the Canton Zurich, Switzerland (KEK-ZH-Nr. 
2012-0427) approved this study. Some patient data of this 
cohort were previously reported.8
Patients with new neurological symptoms between both 
scans and subjects with any kind of treatment (surgical, 
oncological, or radiation) between PET and BOLD-CVR 
imaging were excluded. One patient with 1p/19-codeleted 
anaplastic oligodendroglioma underwent the PET and 
BOLD-CVR mapping 2 times: by a diagnosis of primary 
glioma and by glioma recurrence.
The diagnosis was confirmed with histopathological 
analysis in all primary dffuse gliomas, and if available for 
recurrent gliomas. For the remaining recurrent gliomas 
(6 of 12), the diagnosis of tumor progression as done 
by the treating physicians was based on RANO criteria12 
and confirmed by the interdisciplinary neuro-oncological 
tumor board.
To determine the normal ranges of whole brain and 
hemispheric BOLD-CVR, 19 age- and sex-matched healthy 
subjects were extracted from the same BOLD-CVR data-
base. The criteria for being included within this database 
were healthy adult subjects with no known neurological 
symptoms or intracranial pathologies.
The data that support the findings of this study are avail-
able from the corresponding author upon reasonable 
request.
Image Acquisition and Processing
MRI data were acquired on a 3-T Skyra VD13 (Siemens 
Healthcare, Erlangen, Germany) with a 32-channel head 
coil. BOLD fMRI parameters and a 3-dimensional (3D) 
Importance of the Study
Diffuse gliomas exhibit infiltrative growth be-
yond the standard MRI-detectable tumor lesion. 
An advanced imaging approach with BOLD-CVR 
and metabolic PET can potentially better iden-
tify the extent of diffuse glioma infiltration. We 
were able to show that hypermetabolism and 
impaired cerebrovascular reactivity are present 
beyond the standard MRI-defined tumor 
border, suggesting active tumor infiltration in 
the peritumoral tissue. The hypermetabolism is 
still significantly present 6 mm beyond the vis-
ible glioma lesion, whereas significant BOLD-
CVR impairment is seen up to 12  mm. This 
larger hemodynamic (vascular) impairment 
could be explained by the recently reported 
concept that glioma cells have the ability to 
connect to and integrate into neural circuits in 








































































































T1-weighted Magnetization Prepared Rapid Acquisition 
Gradient Echo (MP RAGE) image were performed. FET-PET 
scans were performed on an ECAT EXACT HRþ scanner 
(Siemens Healthcare, Erlangen, Germany).
BOLD-CVR determination.—During the fMRI se-
quence, the carbon dioxide stimulus was modulated 
by a computer-controlled gas blender with prospective 
gas targeting algorithms (RespirAct; Thornhill Research 
Institute, Toronto, Canada). The RespirAct allows for pre-
cise targeting of arterial partial pressure of oxygen and 
CO2.
13 The controlled hypercapnic stimulus was given to 
patients during the BOLD-CVR study, as previously pub-
lished.14,15 All the acquired raw BOLD fMRI volumes were 
transferred to an external computer and preprocessed 
with SPM 12 (Statistical Parameter Mapping Software; 
Wellcome Department of Imaging Neuroscience, 
University College of London, London, UK). The BOLD 
fMRI volumes were aligned to the T1-weighted MP RAGE 
image and were smoothed with a Gaussian Kernel of 6 
(for more information, see Sebök et al., 2018, Methods).14 
Next, a voxel-wise temporal shifting for optimal physio-
logical correlation of the BOLD signal and CO2 time series 
was performed. CVR, defined as the percentage BOLD 
signal change/mmHg CO2, was then calculated from the 
slope of a linear least-square fit of the BOLD signal time 
course to the CO2 time series over the range of the first 
baseline of 100 s, the step portion of the protocol (80 s) 
and the second baseline of 100  s on a voxel-by-voxel 
basis. The extra BOLD fMRI volumes were acquired to 
allow for the potential temporal shift. The CVR calcula-
tions were done as described.16
Metabolic PET studies: FET-PET and FDG-PET. 
—FET-PET scans were performed on an ECAT EXACT 
HRþ scanner, which acquires 63 contiguous trans-axial 
planes, simultaneously covering 15.5  cm of the axial 
field of view. After a 15-min transmission scan (germa-
nium-68 sources), a target dose of 185 MBq of FET was 
injected intravenously. PET acquisition in 3-dimensional 
mode was started 30–40  min after injection (128 × 128 
matrix). Data were reconstructed by filtered back-projec-
tion using a Hann filter after correction for scattering and 
attenuation.
One patient underwent [18F]2-fluoro-2deoxy-D-glucose 
positron emission tomography with computer tomog-
raphy (FDG-PET CT) study. The early FDG-PET scans were 
started 40–45 min after the administration of 8–15 mCi F-18 
FDG using a hybrid PET/CT system (Ingenuity, TF PET/CT/
Philips, the Netherlands), and the delayed PET/CT scans 
were performed at 75  min after the early scan. CT data 
were acquired first and the following parameters were 
used: tube rotation time, 0.5 s per revolution; 120 kV; 140 
mAs; reconstructed slice thickness, 5 mm. After the acqui-
sition of CT data had been completed, the tabletop with the 
patient automatically advanced into the PET-sensitive field 
of view and acquisition of PET data was started in 3-dimen-
sional mode with the patient in exactly the same position 
on the table. Scanning was performed in one-bed position 
for 3  min. The attenuation correction was automatically 
completed using corresponding CT data.
Volumes of Interest Determination
Three-dimensional tumor masks were determined and 
manually drawn from the current state-of-the-art MRI pro-
tocol by a neuroradiologist with more than 20 years of ex-
perience (A.P.) using iPlan software (BrainLab AG, Munich, 
Germany). The tumor borders were drawn on every slice 
of the T1-weighted contrast enhanced scan where the 
tumor was visible, or on every slice of FLAIR and/or T2 
sequences in case of absent contrast enhancement. For 
contrast-enhancing tumors, the borders were confirmed 
and/or adapted regarding the expansion on FLAIR and T2 
sequences obtaining a 3-dimensional spherical volume of 
interest (VOI).
These tumor masks were overlaid on the BOLD-CVR and 
PET maps to obtain mean intralesional values in those spe-
cific regions. Automated spherical 3-dimensional concen-
tric VOIs17 of 6 mm width starting from the tumor border 
outward up to 30  mm (5 VOIs) were created to perform 
peritumoral tissue analysis. These VOIs were overlaid on 
the BOLD-CVR and -PET maps to obtain tumor volume, 
whole brain, gray matter, and white matter mean BOLD-
CVR and FET-PET/FDG-PET values. On the contralateral 
hemisphere in mirror-like anatomical regions (ie, flipped 
analysis), the same analysis was performed to confirm im-
paired peritumoral hemodynamic.
Statistical Analysis
We performed a statistical analysis using SPSS Statistics 
26 (IBM Corp., Armonk, NY). Means of normally distrib-
uted continuous variables from IDH-mutant WHO grade 
III and IDH-wildtype IV glioma groups were compared by 
an independent Student’s 2-tailed t test, where P < .05 was 
considered statistically significant. Each VOI was analyzed 
separately and a comparison between affected and contra-
lateral (ie, flipped) hemisphere was made for BOLD-CVR 
and FET-PET using paired t test. Moreover, paired t test was 
used to identify differences between BOLD-CVR and PET 
values of VOIs for the whole cohort.
Results
Study Population Characteristics
A flow chart illustrating subject inclusion can be found 
in Figure 1. Eighteen patients (19 datasets) with diffuse 
gliomas with mean age 52.4 ± 12.3, 16 males (84%), and 
19 age- and sex-matched healthy subjects were included 
(Table 1). The mean CO2 step-change (in mmHg) was sim-
ilar for diffuse glioma patients and healthy subjects (8.4 ± 
1.5 vs 8.3  ± 1.6). A  detailed overview of all patient and 
glioma characteristics can be reviewed in Supplementary 
Table 1.
We studied a cohort of IDH-mutant WHO grade III glioma 


















































































 4 Sebök et al. Diffuse gliomas’ peritumoral environment
anaplastic oligodendroglioma) or IDH-wildtype tumors (n = 7 
with glioblastoma), 7 of them at primary diagnosis and 12 
at tumor recurrence. One patient with anaplastic oligo-
dendroglioma underwent the PET and BOLD-CVR mapping 
2 times—by a diagnosis of primary glioma and by glioma re-
currence—resulting in 19 datasets. Patients with WHO grade 
III tumors (n = 12) were significantly younger. Other baseline 
characteristics between both groups were comparable.
BOLD-CVR Findings in Patients With Diffuse 
Gliomas Versus Healthy Subjects
Patients with diffuse gliomas show significantly impaired 
whole-brain CVR as compared to the healthy cohort (ie, 
whole-brain mean CVR value ± standard deviation [SD] 
for diffuse glioma patients vs healthy subjects: 15 ± 0.08 
vs 0.21  ± 0.08; P  =  .04). For gray matter CVR, a distinct 
  
Table 1. Relevant Characteristics of Glioma Patients and Healthy Controls
Glioma Cohort (N = 19) Healthy Cohort (N = 19) P
Age (mean ± SD) 52.4 ± 12.3 52.2 ± 12.0 .96
Sex, male (%) 16 (84.2) 16 (84.2) n.a.
Mean CVR whole brain 0.15 ± 0.08 0.21 ± 0.08 .04
Mean CVR gray matter 0.18 ± 0.08 0.24 ± 0.09 .03
Mean CVR white matter 0.12 ± 0.08 0.15 ± 0.05 .24
Mean CVR affected hemispherea 0.16 ± 0.08 0.20 ± 0.08 .06
Mean CVR unaffected hemispherea 0.16 ± 0.08 0.21 ± 0.08 .07
CVR, cerebrovascular reactivity; N, number; SD, standard deviation.
aFor a healthy cohort, the right hemisphere was defined as affected and the left hemisphere as unaffected.
  
  
140 subjects with BOLD-CVR study
60 patients with gliomas
80 healthy subjects
36 patients with BOLD-CVR without a
corroborating FET-PET/FDG-PET imaging
24 patients with BOLD and PET imaging
available prior to treatment*
2 patients with non-diffuse gliomas
3 patients with both scans with > 6
weeks time interval
19 patients with diffuse gliomas
(either WHO grade III or IV)**
19 age-and sex-matched healthy controls
sligible for inclusion
38 subjects included in analysis
(19 age- and sex-matched pairs)
Figure 1. Study flow chart. From the prospective database with 140 subjects who underwent BOLD-CVR study, 60 patients were diagnosed with 
glioma and 80 were healthy subjects. From 60 glioma patients, 24 patients underwent BOLD and PET imaging prior to treatment (*no treatment [ie, 
no surgery] done for primary gliomas, no second-line therapy initiated for recurrent glioma) in the time frame of 6 weeks. Two patients with non-
diffuse glioma and 3 patients with more than 6 weeks interval between BOLD-CVR and PET scans were excluded from the study. Nineteen subjects 
with diffuse glioma (either WHO grade III or IV) were eligible for further analysis. **The diagnosis was confirmed with histopathological analysis 
for all primary diffuse gliomas, and if available for recurrent gliomas. For the remaining recurrent gliomas, diagnosis of progression was done by the 
treating physicians and based on RANO criteria.12 From 80 healthy subjects who underwent the BOLD-CVR study, we extracted 19 age- and sex-








































































































difference was also seen (P = .03), whereas no difference 
was found for white matter CVR (Table 1).
BOLD-CVR Findings in Patients With IDH-Mutant 
(WHO Grade III) Versus IDH-Wildtype (WHO 
Grade IV) Glioma
No differences in whole-brain CVR, gray and white matter 
CVR were seen between patients with IDH-mutant and IDH-
wildtype tumors. Furthermore, tumor volume, CVR, and 
PET values of the tumor did not show significant differences 
between both groups. The individual mean CVR values 
and P values can be reviewed in Supplementary Table 2. 
Representative BOLD-CVR and PET illustrations of one subject 
with recurrent WHO grade IV glioma are presented in Figure 2.
BOLD-CVR and PET Finding of Perilesional Brain 
Tissue: Concentric, Expanding VOI Analysis up 
to 30 mm From the Visible Glioma Lesion
BOLD-CVR and VOI analysis.—Since we did not find sta-
tistically relevant differences in CVR and PET values between 
patients with IDH-mutant and IDH-wildtype (WHO grade III 
and IV) glioma, we allowed us to use the entire cohort as one 
group for the VOI analysis of the peritumoral region. These 
VOIs consisted of 6-mm-wide volumes that were concentri-
cally expanded up to 30 mm from the visible glioma lesion. 
Two datasets of the patient with right-sided glioma crossing 
the midline (patients who underwent BOLD imaging initially 
by primary tumor diagnosis and by a diagnosis of tumor 
recurrence) were excluded from this analysis since no ref-
erence contralateral hemisphere (ie, flipped analysis) was 
available for these datasets.
Tables 2 and 3 represent the differences in CVR and 
PET values between the affected hemisphere and flipped 
(contralateral) hemisphere for the tumor and the concen-
trically expanded VOIs up to 30 mm of the visible glioma 
lesion. The hemisphere containing the diffuse glioma (ie, 
affected hemisphere) exhibited significantly more im-
paired CVR than the contralateral unaffected hemisphere 
(mean CVR: 0.03 ± 0.07 vs 0.11 ± 0.08; P < .001). Moreover, 
a difference is seen between the first and second VOI of 
affected and unaffected hemisphere (0.07 ± 0.06 vs 0.11 ± 
0.06; P = .002 and 0.10 ± 0.08 vs 0.13 ± 0.04; P = .02, re-
spectively). A trend toward normalization of CVR values 
is observed beginning at an 18  mm distance (ie, VOI 
3) from the visible glioma lesion (Table 2 and Figure 3).
Calculating the differences between CVR of the tumor le-
sion and the VOIs of the affected hemisphere, distinct dif-
ferences in mean CVR values of the tumor and VOI 1, VOI 1 
and VOI 2, as well as VOI 2 and VOI 3 are seen (CVR tumor 
vs VOI 1: 0.03 ± 0.07 vs 0.07 ± 0.06, P < .001; VOI 1 vs VOI 
2: 0.07 ± 0.06 vs 0.10 ± 0.08, P < .001; VOI 2 vs VOI 3: 0.10 ± 
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Figure 2. Representative imaging data of one patient with glioblastoma. A 52-year-old male patient with left-sided temporal glioblastoma (WHO 
grade IV) was diagnosed and macroscopically completely resected in February 2016. In November 2017, the patient presented with recurrent tumor 
temporal on the left side. He underwent a BOLD-CVR and PET study in a time frame of 6 days and before the microsurgical resection of the recur-
rent glioma. BOLD-CVR showed impaired CVR clearly beyond the tumor borders as seen in T1-contrast-enhanced images. FET-PET images showed 




















































































 6 Sebök et al. Diffuse gliomas’ peritumoral environment
impairment toward the tumor core. In this regard, no dif-
ferences between each VOIs are present in the contralateral 
(“flipped”) hemisphere analysis.
Metabolic PET and VOI analysis.—The standard MRI-
defined glioma lesion shows significantly higher PET 
values compared to the contralateral unaffected hemi-
sphere (2.76 ± 3.32 vs 1.54 ± 2.03; P  =  .012), indicating 
hypermetabolism. Calculating the difference of the PET 
values for the VOIs between the affected and contralat-
eral hemispheres, a marked difference is seen only for 
the first VOI (affected hemisphere vs unaffected hemi-
sphere: 2.25 ± 2.42 vs 1.68 ± 2.28; P = .05). Twelve milli-
meters distant from the hypermetabolic visible glioma 
lesion (ie, VOI 2), a trend toward normalization of the 
PET values is seen (Table 3 and Figure 3).
In agreement with the BOLD-CVR findings, the PET VOI 
analyses show a difference between glioma PET values 
and the first 3 VOIs (PET tumor vs PET VOI 1: 2.76 ± 3.32 
vs 2.25  ± 2.42, P  =  .05; VOI 1 vs VOI 2: 2.25  ± 2.42 vs 
1.79 ± 1.88, P = .04; VOI 2 vs VOI 3: 1.79 ± 1.88 vs 1.61 ± 
1.76, P = .05), indicating increasing metabolism toward 
the tumor core. No significant differences between VOIs 
are seen for the contralateral (“flipped”) hemisphere for 
this analysis.
Discussion
In this study, we demonstrate hypermetabolism and im-
paired CVR beyond the standard MRI-defined diffuse glioma 
lesion (ie, beyond the T1 contrast-enhancing lesion and/or T2/
FLAIR-defined tumor border), suggesting active tumor infil-
tration in the peritumoral environment. The hypermetabolism 
is still significantly present 6 mm beyond the visible glioma 
lesion, whereas significant BOLD-CVR impairment is seen up 
to 12 mm. The potential implications, however, point toward a 
better identification of diffuse glioma tissue infiltration which 
may improve therapeutic planning and prognostic evaluation 
in the future. In clinical routine, advanced PET and BOLD-CVR 
multimodal assessment can be conducted as a single exami-
nation when using a PET-MRI system.
The Meaning of Hemodynamic Impairment and 
Hypermetabolism Beyond the Standard MRI-
Defined Diffuse Glioma Borders
Our results showed that in the immediate vicinity of the 
tumor environment, there is both hypermetabolism (up to 
6 mm) and impaired CVR up to 12 mm beyond the visible 
diffuse glioma lesion. This larger hemodynamic (vascular) 
  
Table 3. Impact of Supratentorial High-Grade Glioma on Surrounding Brain Tissue: PET Findings
PET Affected Hemisphere (N = 17a) PET Contralateral Hemisphere (N = 17a) P
Supratentorial tumor 2.76 ± 3.32 1.54 ± 2.03 .012
VOI 1 (6 mm) 2.25 ± 2.42 1.68 ± 2.28 .05
VOI 2 (12 mm) 1.79 ± 1.88 1.59 ± 2.42 .26
VOI 3 (18 mm) 1.61 ± 1.76 1.62 ± 2.18 .67
VOI 4 (24 mm) 1.59 ± 1.64 1.62 ± 2.21 .95
VOI 5 (30 mm) 1.60 ± 1.95 1.67 ± 2.30 .54
N, number; PET, positron emission tomography; VOI, volume of interest.
aTwo datasets of patients with right-sided glioma crossing the midline were excluded from calculations.
  
  
Table 2. Impact of Supratentorial High-Grade Glioma on Surrounding Brain Tissue: BOLD-CVR Findings
CVR Affected Hemisphere (N = 17a) CVR Contralateral Hemisphere (N = 17a) P
Supratentorial tumor 0.03 ± 0.07 0.11 ± 0.08 <.001
VOI 1 (6 mm) 0.07 ± 0.06 0.11 ± 0.06 .002
VOI 2 (12 mm) 0.10 ± 0.08 0.13 ± 0.04 .02
VOI 3 (18 mm) 0.12 ± 0.06 0.14 ± 0.06 .20
VOI 4 (24 mm) 0.14 ± 0.09 0.15 ± 0.08 .45
VOI 5 (30 mm)  0.15 ± 0.06 0.15 ± 0.07 .88
CVR, cerebrovascular reactivity; N, number; VOI, volume of interest.








































































































impairment could be explained by the recently reported 
concept that glioma cells have the ability to connect to and 
integrate into neural circuits in the brain with the forma-
tion of neuron–glioma synapses (ie, co-option). The cancer 
cells themselves are promoting the neuronal activity that 
then feeds back to drive the growth of cancer. This could 
explain why gliomas behave in the way they do—in-
stead of forming a large mass, cancer tends to intertwine 
throughout the brain.18 Moreover, bidirectional interac-
tion between neuron–glioma is present; neuronal activity 
increases glioma growth,19 and gliomas are thought to 
increase neuronal activity.18 Under normal conditions, it 
is believed that neurons dictate vasodilatation in response 
to higher levels of CO2 resulting in a subsequent increase 
in cerebral blood flow, ie, physiological neurovascular 
coupling.20,21 Preliminary data in diffuse glioma infer dis-
ruption of this coupling mechanism, where perilesional vi-
able neurons cannot enhance regional cerebral blood flow 
(termed “neurovascular uncoupling”),6,7,11,22 a phenom-
enon that may be more pronounced with increasing tumor 
volume.8,23
This may be related to vascular dysregulation due to 
tumor neoangiogenesis and altered autoregulation due 
to the co-option of tumor cells accumulating around the 
existing vasculature. As a result, the blood vessel walls 
are destabilized with decreased pericyte coverage, cells 
thought to be involved in blood flow autoregulation,20 
leading to the inability of viable neurons to enhance re-
gional cerebral blood flow, something that can be as-
sessed with CVR. In this regard, recent studies reported the 
presence of peritumoral or even more extended regional 
impaired CVR, something that was not found for patients 
harboring low-grade gliomas.8,24,25
Supratentorial Hemodynamic and Metabolic 
Impairment in Diffuse Glioma
Several previous studies have proven the clinical value 
of FET-PET imaging to determine the extent of cerebral 
gliomas for treatment planning, biopsy guidance, de-
tection of tumor recurrence, prognosis, and treatment 
monitoring.26–28 However, our results suggest a poten-
tial additional benefit of concomitant BOLD-CVR imaging 
since a more extended perilesional hemodynamic impair-
ment was found as compared to the hypermetabolism de-
tected with PET.
As for our cohort, diffuse glioma represents a hetero-
geneous disease. In particular, recurrent gliomas also ex-
hibit radionecrosis and/or gliosis tissue with hyalinized 
vessels,29,30 which impacts CVR and metabolism. Wiestler 
et al.31 presented a multiparametric MRI-based differen-
tiation of WHO grade II/III glioma and glioblastoma with 
BOLD MRI measurement of oxygen extraction fraction 
(rOEF) in glioma patients. Among 37 patients with pri-
mary gliomas based on multiple MRI modalities (rOEF 
and perfusion imaging), the WHO grade was correctly 
predicted in 91.8% of patients. The study suggested that 
multimodal noninvasive MRI information reflects the un-
derlying tumor biology and showed the importance of 
the development of the field of radiogenomics. In this 
regard, the suspected ability of radiological multimodal 
diffuse glioma characterization is a promising develop-
ment for both glioma diagnosis and treatment. However, 
we have to be aware that this largely depends on the 
quality of the data (ie, better tumor depiction and multi-
modal imaging characteristics), which may also improve 





































Tumorlesion VOI 1 VOI 2 VOI 3 VOI 4 VOI 5Tumorlesion VOI 1 VOI 2
A B





























Figure 3. CVR and PET impact of diffuse gliomas on surrounding brain tissue. (A) Line plot of mean CVR values around diffuse glioma. The plot de-
picts the increase in mean CVR values from the diffuse glioma outward in the surrounding “healthy” brain tissue and also shows lower CVR values 
in the affected hemisphere. BOLD-CVR values represent the mean values of the 2 hemispheres (red line for affected hemisphere and blue line for 
flipped hemisphere). (B) Line plot of mean PET values around diffuse glioma. The plot depicts the decrease in mean PET values from the diffuse 
glioma outward in the surrounding “healthy” brain tissue and also shows higher PET values in the affected hemisphere. PET values represent the 
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Limitations
In this preliminary study, we have only included 19 datasets 
of 18 patients with diffuse glioma, numbers that are sim-
ilar to other studies investigating metabolic and hemody-
namic alterations in gliomas.31–33 Therefore, the results 
should be interpreted with caution. Second, this was a 
retrospective analysis of prospectively collected data. The 
third important limitation of our study is that we included 
a mixed cohort of diffuse glioma patients with WHO grade 
III and grade IV gliomas as well as primary and recurrent 
gliomas. Recurrent gliomas are often not a homogenous tu-
morous tissue that can affect our data. Moreover, for 6 of 
12 patients with recurrent tumors, no histological tissue at 
tumor recurrence is available and diagnosis of tumor pro-
gression as done by the treating physicians was based on 
RANO criteria,12 which might not fully exclude that areas 
of radionecrosis contribute to the radiological properties 
of the tumor. Furthermore, the included patients under-
went a metabolic imaging with either FET-PET or FDG-PET. 
A  well-known physiological limitation of the BOLD-CVR 
technique—imaging resolution and smoothing technique—
could affect the BOLD-CVR values in the first VOI around the 
anatomically defined tumor lesion. To overcome this limita-
tion, for our future projects, we are planning to determine 
BOLD-CVR values around the PET-determined tumor lesion, 
meaning in the peritumoral tissue with PET enhancement 
but without contrast agent enhancement. Since gliomas 
are very infiltrative tumors using the contralateral hemi-
sphere for flipped VOI analysis, an occult tumor tissue as 
a confounder could be introduced. The analysis using the 
infratentorial normalization would allow for the normali-
zation of each ring and a more optimal intersubject com-
parison. However, our aim was to compare the tissue in 
different rings supratentorial to the same tissue contralat-
eral (using an intrasubject analysis). This confounder would 
result in a type 2 error (false negative).
Conclusions
In patients with diffuse glioma, we demonstrate 
hypermetabolism and impaired CVR beyond the MRI-
detectable tumor border, suggesting active tumor infiltra-
tion in the peritumoral microenvironment. This advanced 
multimodal imaging approach can potentially better 
identify the extent of erratic infiltration of diffuse gliomas; 
however, its merit needs to be confirmed prospectively.
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Supplementary material is available at Neuro-Oncology 
Advances online.
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